Nonoxynol-9 Proposed Irritation/STD Infection Warning Revisions Requested
This article was originally published in The Tan Sheet
Executive Summary
FDA's proposed label warning for OTC nonoxynol-9- containing vaginal contraceptives cautioning that frequent use may increase the risk of infection with HIV or other sexually transmitted diseases "is not sufficiently supported by the scientific literature," Apothecus Pharmaceutical maintains in recent comments to the agency
You may also be interested in...
Vaginal Contraceptive N-9 Label Warnings Urged “As Soon As Possible” – FDA
Manufacturers of vaginal contraceptives containing nonoxynol-9 should voluntarily implement proposed label warnings about increased vaginal irritation and HIV infection risk "as soon as possible," FDA advises in a 1Jan. 16 proposed rule
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands